Company: WENNU
Filing Date: 2025-03-28
Form Type: DRS/A
Source: 0001013762-25-004273
Chunk: 161

Company: WEN Acquisition Corp
Filing Date: 2025-03-28
Form: DRS/A
Chunk 161
---
 with PWP Holdings LP (NASDAQ: PWP) in June 2021. None of FinTech IV’s public shares were redeemed in connection with the business combination. PIPE investors committed to purchase an aggregate of $125.0million in common stock, at a price of $10.00 per share. PWP’s closing price on March24, 2025 was $20.58 per share. • FTAC Olympus Acquisition Corp.: Ryan Gilbert, one of our advisors, served as Chief Executive Officer, President and a director, and Mr. Patel served as Chief Operating Officer, to FTAC Olympus Acquisition Corp. (NASDAQ: FTOC) (“FTOC”). FTOC, after its initial public offering of $755 million in August 2020, consummated its initial business combination with Payoneer Global Inc. (NASDAQ: PAYO) in June 2021. In connection with the business combination, approximately 23.9% of FTAC Olympus’ public shares were redeemed. PIPE investors committed to purchase an aggregate of $300.0million in common stock, at a price of $10.00 per share. Payoneer’s closing price on March24, 2025 was $7.59 per share. • Locust Walk Acquisition Corp.: Mr. Gilbert and Mr. Patel served as advisors to Locust Walk Acquisition Corp. (NASDAQ: LWAC) which merged with eFFECTOR therapeutics (NASDAQ: EFTR) in August 2021 (in which approximately 97.0% of LWAC’s public shares were redeemed). PIPE investors committed to purchase an aggregate of $60.7million in common stock, at a price of $10.00 per share. eFFECTOR therapeutics effected a wind down in June 2024 and no longer trades on an exchange. • Phoenix Biotech Acquisition Corp.: Mr.Gilbert and Mr.Patel served as advisors to Phoenix Biotech Acquisition Corp. (NASDAQ: PBAX), which merged with CERo Therapeutics (Nasdaq: CERO) in February 2024 Phoenix Biotech Acquisition Corp. experienced redemptions of approximately 92.6% of its public shares in connection with an extension in December 2022, approximately 40.6% of the remaining public shares in connection with an extension in July 2023, approximately 1.5% of the remaining public shares in connection with an extension in January 2024 and approximately 89.1% of the remaining public shares in connection with